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Abstract
Background: Glioblastoma multiforme (GBM) is the most aggressive type of malignant primary brain tumors in adults.
Molecular and genetic analysis has advanced our understanding of glioma biology, however mapping the cellular
composition of the tumor microenvironment is crucial for understanding the pathology of this dreaded brain cancer. In this
study we identified major cell populations attracted by glioma using orthotopic rodent models of human glioma
xenografts. Marker-specific, anatomical and morphological analyses revealed a robust influx of host cells into the main
tumor bed and tumor satellites.
Methodology/Principal Findings: Human glioma cell lines and glioma spheroid orthotopic implants were used in rodents.
In both models, the xenografts recruited large numbers of host nestin-expressing cells, which formed a ‘network’ with
glioma. The host nestin-expressing cells appeared to originate in the subventricular zone ipsilateral to the tumor, and were
clearly distinguishable from pericytes that expressed smooth muscle actin. These distinct cell populations established close
physical contact in a ‘pair-wise’ manner and migrated together to the deeper layers of tumor satellites and gave rise to
tumor vasculature. The GBM biopsy xenografts displayed two different phenotypes: (a) low-generation tumors (first in vivo
passage in rats) were highly invasive and non-angiogenic, and host nestin-positive cells that infiltrated into these tumors
displayed astrocytic or elongated bipolar morphology; (b) high-generation xenografts (fifth passage) had pronounced
cellularity, were angiogenic with ‘glomerulus-like’ microvascular proliferations that contained host nestin-positive cells.
Stromal cell-derived factor-1 and its receptor CXCR4 were highly expressed in and around glioma xenografts, suggesting
their role in glioma progression and invasion.
Conclusions/Significance: Our data demonstrate a robust migration of nestin-expressing host cells to glioma, which
together with pericytes give rise to tumor vasculature. Mapping the cellular composition of glioma microenvironment and
deciphering the complex ‘crosstalk’ between tumor and host may ultimately aid the development of novel anti-glioma
therapies.
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Introduction
Despite advances in surgical, radiation and chemotherapy
treatments, patients with glioma have poor prognosis, with a
median survival of 15 months and a 5-year survival rate less than
10% [1,2,3]. A more comprehensive understanding of glioma
biology, including the role of the tumor microenvironment and
tumor-host cellular crosstalk, is needed to develop more effective
therapies for glioblastoma multiforme (GBM) [4].
In the adult brain, neural stem cells (NSCs) are a subpopulation
of specialized astrocytes found in the subventricular zone (SVZ) of
the lateral ventricles and the subgranular zone of the hippocampal
dentate gyrus [5,6], which have been implicated in learning,
memory and in tissue regeneration [7,8]. NSCs that originate in
the SVZ of the rodent brain travel several millimeters in the rostral
migratory stream to the olfactory bulb, where they differentiate
into interneurons, which have been implicated in continuous
replacement of neurons [9,10]. NSCs in the subgranular layer of
the hippocampus display a restricted migratory capacity and
contribute to the genesis of dentate gyrus granule cells [10].
There has been longstanding interest in the medical and
scientific community to develop NSCs for therapeutic purposes
within the central nervous system, including NSC-mediated
therapeutic gene delivery to malignant gliomas [11,12,13,14,15].
Although therapeutic studies are based on the transplantation of
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exogenous, genetically-modified NSC lines, one may envision that
stimulating endogenous stem cells may serve as a means of
antitumor therapy. Indeed, studies suggest that ‘naı¨ve’, genetically-
unmodified NSCs also have therapeutic effects [16] and that
endogenous NSCs mobilized to gliomas have antitumor efficacy
[17]. A greater understanding of the distribution, tropism and
migratory routes of endogenous NSCs to gliomas will aid in the
development of novel neurotherapeutics.
Previous studies of endogenous NSC homing to gliomas have
mostly evaluated glioma cell line-based rodent tumors [17,18].
The aim of our study was to investigate tumor-host interactions in
animal models of orthotopic human glioma xenografts, with an
emphasis on host-derived neural stem/progenitor cells (NSPCs)
and endothelial progenitors [19] [20]. Our model allows to clearly
distinguish between nestin-expressing cells derived from the
human xenograft versus the host (mouse or rat)-derived nestin
positive cells. Such distinction between these cell populations was
made possible by using exclusively human-specific and exclusively
mouse/rat-specific nestin antibodies, and double immunostaining
methods that we have developed for use of primary antibodies
when they are derived from the same species (e.g., mouse). We
evaluated the contribution of endothelial progenitors to tumor
angiogenesis. In addition to stem and progenitor cells, we
investigated other cell populations that are known to be present
in glioma and the tumor niche, such as astrocytes (identified by
glial fibrillary acidic protein, GFAP) and pericytes that line the
blood vessels (smooth muscle actin, SMA), and we assessed cell
proliferation, migration and invasion. We determined the
migration pattern, morphology and cell proliferation of host
rodent neural precursors (identified by nestin expression) in
response to implantation of three different human glioma cell
lines (U251, U87, D566), as well as biopsy spheroids from GBM
patients, which resulted in a panel of xenografts with differing
growth patterns and invasiveness. We observed that host nestin-
positive cells that originated in the SVZ ipsilateral to the tumor
implant migrated towards the xenograft borders and deeper into
the tumor regions. The observation that rodent nestin-positive
cells were recruited to the parenchyma and neovasculature of
glioma xenografts suggests a ‘crosstalk’ between the human tumor
and rodent host compartments. Although the precise role of
infiltrating NSPCs and endothelial progenitors in tumor progres-
sion is still poorly defined, we provide evidence for a putative role
in tumor engraftment, invasion and angiogenesis.
Results
Host nestin-positive cells are attracted to glioma
implants
The human glioma cell lines U251, U87 and D566 cell lines
used in our current study were originally generated from
malignant glioma patient material, and the take rates, immuno-
genicity and growth patterns of their lesions have been
characterized previously [21,22]. We found that all glioma cell-
line based xenografts grew as hypercellular, pleomorphic and
angiogenic with moderate (U251, D566) or little invasion (U87)
into normal brain tissue. Although U251 tumors showed sharp,
‘pointy’ invasive protuberances, U87 tumors grew as large bulky
tumors and displayed round, well-demarcated small satellites in
the vicinity of the main tumor mass (occasionally we observed U87
small tumor satellites in the hemisphere contralateral to tumor
implantation). Tumors from all three cell lines displayed some
level of necrosis in the main tumor mass, but tumor satellites of
U87-derived tumors were devoid of necrotic regions.
Mouse nestin-expressing cells were recruited to all three cell line
xenografts, with a greater density of host cells observed at the
tumor periphery in U251 xenografts (Fig. 1A). Composite images
of DAPI-stained horizontal brain sections revealed the periven-
tricular location of the xenograft in the right hemisphere, with
boxes indicating magnified areas of interest in the ipsilateral and
contralateral hemispheres (Fig. 1B, C). At high magnification, host
nestin-positive cells were detected throughout the tumor, and a
high density of such infiltrating cells was observed at the tumor
periphery (Fig. 1D) and in deeper tumor regions, where clusters of
host nestin-positive cells were also observed (Fig. 1F). Regions of
tumor that appeared to be necrotic (depleted of DAPI stained cell
nuclei) were surrounded by a halo of host nestin-positive cells
(Fig. 1F), whereas the area lining the ventricle contralateral to the
tumor had only few host nestin-positive cells (Fig. 1E). Host nestin-
positive cells appeared to originate in the subventricular zone
(SVZ) ipsilateral to the tumor implant, and were present in the
ipsilateral SVZ at some distance (1–3 mm) from the tumor mass
(Fig. 1F). Double-staining for human nestin (tumor) and mouse
Figure 1. Host nestin-expressing cells are mobilized by human
glioma xenografts in the mouse brain. Mouse nestin-positive cells
(green) at the tumor border and peritumor brain tissue, as well as in
deeper regions of the tumor mass (A, D) (boxed area on the left in B is
shown enlarged in A and D). A mouse brain implanted with U251
human glioma cells (horizontal section; DAPI, blue) (B). Note the high
cell density in the xenograft compared to the normal brain tissue.
Higher magnification images of the lateral ventricle (hemisphere
contralateral to the tumor) showing mouse nestin-expressing NSPCs
(green, arrows) (C, E). Note the scarcity of nestin-positive cells and
apparent lack of migration by these cells, suggesting little or no
proliferation and migration by NSPCs from this region to the tumor.
Recruitment of host nestin-positive cells (green) in the subventricular
layer of the lateral ventricle ipsilateral to the tumor (F) (arrowheads
indicate the wall of lateral ventricle). In this section, the lateral ventricle
stretches from the hippocampal formation (caudal) toward the corpus
callosum (rostral). Arrowheads show the apparent migration trajectory
and pattern of NSPCs along fiber tracts of the deep cerebral white
matter. Double-immunostaining for human (red) and mouse nestin
(green) in the tumor, showing interdigitation of human and mouse cells
(G). lv, lateral ventricle. Bars A, C, D, E, G 100 mm, F 500 mm, B 1 mm.
doi:10.1371/journal.pone.0035150.g001
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nestin (infiltrating host cells) revealed an interdigitation of host
nestin-positive cells with human glioma cells in the tumor (Fig. 1G).
Host nestin-positive cells migrate to the main tumor
mass and small tumor satellites
In the U87 human glioma xenograft model, both the primary
lesion and small tumor satellites stained uniformly for human
nestin (Fig. 2A). Mouse nestin-positive cells encapsulated and
infiltrated small tumor satellites both in the ipsilateral and
contralateral side (Fig. 2B, D). Encapsulation of small tumor
satellites by mouse nestin-positive cells was seen in satellites of sizes
both smaller and larger than 100 mm, whereas infiltration by
mouse nestin-positive cells was more pronounced in satellites that
were .100 mm. Many of these mouse nestin-positive cells had rich
arborizations, showing morphological similarity to astrocytes
(Fig. 2B, D, E), while mouse nestin-positive infiltrating cells
displayed a more elongated, spindle-shaped morphology (Fig. 2F).
Blood microvessels in the tumor xenograft core stained intensely
for mouse nestin (Fig. 2C), which suggests the contribution of host
mouse nestin-positive cells to glioma angiogenesis. Nestin
expression was seen in all tumor blood vessels covering the
endothelial surface.
Invasive and angiogenic GBM xenografts attract host
nestin-positive cells
The biopsy xenograft model used in our study has been
previously described and characterized [23,24,25]. We generated
multicellular spheroids from glioma biopsies obtained from
patients without passaging in monolayers. In contrast to glioma
cell lines, the spheroids preserve the original tissue architecture of
the human tumor, as well as other genotypic and phenotypic traits
such as DNA ploidy and expression of tumor markers [26,27,28].
When intracranially transplanted into nude rats, the spheroids
retain the same cellular phenotype, genotype and invasive growth
as the patient tumor [23].
We observed that the GBM biopsy spheroid xenografts in rats
displayed two distinct phenotypes. When the xenografts were
generated directly from patient material, the lesions were highly
invasive, had low cell density and grew without angiogenesis.
Glioma cells infiltrated the whole ipsilateral hemisphere and
invaded the opposite hemisphere through the corpus callosum
(Fig. 3A). However, xenografts generated from tumors that had
been grown for several generations as serial in vivo passages in rat
brains started to display dilated vessels, showed greater cell density,
and exhibited only local invasion into brain tissue (Fig. 3B). Some
of the high (fifth)-generation lesions included glomeruloid
microvascular proliferations that recapitulated the morphological
features observed in patients with GBM. Similar to what we
observed in glioma cell-line implants in mice, glioma xenografts in
rats displayed a halo of nestin-positive host cells that was localized
to the tumor border and peritumor areas (Fig. 3C, D, E). Human
nestin expression was uniform and robust in the tumor cells both
in low- and high generation lesions (Fig. 3D, E). In addition,
elongated host cells, with several processes, diffusely infiltrated the
tumor edge and accumulated around brain vessels close to the
xenograft (Fig. 3E). The elongated morphology of these infiltrating
cells may suggest that they are moving towards their ‘destination’
within or adjacent to the tumor mass, especially to tumor blood
vessels.
We next investigated the expression of rodent nestin in the
context of angiogenesis in rat brains bearing xenografts of GBM
biopsy spheroids or that lacked such xenografts. In normal rat
brains, nestin-expressing NSPCs were seen in the walls of the third
ventricle (Fig. 4A) and the lateral ventricles, and the majority of
cortical microvessels showed little or no nestin expression (Fig. 4B).
However, in high-generation xenografts, staining for host nestin
highlighted all tumor blood vessels (Fig. 4C) with a sharply defined
endothelium-specific labeling pattern comparable to labeling with
the endothelial marker, von Willebrand factor (data not shown).
Markedly dilated vessels with irregular morphology were found
close to the necrotic areas in the GBM xenografts. Rat nestin was
similarly expressed in blood vessel walls in the immediate
peritumor area and the tumor edge as well, although in these
areas the microvessels assumed a normal (non-dilated) morphol-
ogy. Strong nestin immunolabeling was also detected in normal-
appearing, non-dilated microvessels in highly invasive lesions
resembling gliomatosis cerebri in the low-generation, invasive
GBM xenografts (Fig. 4D).
Distribution and morphology of host nestin-positive cells
in invasive and angiogenic glioma
In order to gain insight into the identity nestin-positive cells
attracted by glioma, we studied the morphology of tumor-
Figure 2. Mouse nestin expressing cells with different mor-
phologies populate the primary tumor bed and the glioma
small satellites. Immunostaining of U87 human glioma tumor bed
and satellites) for human nestin (A) (arrowheads indicate tumor
satellites). Host mouse nestin-expressing cells with rich arborizations
encapsulate and infiltrate the tumor satellites observed in U87
xenografts (B, D, E). Mouse nestin-expressing cells form blood vessels
in the main tumor mass (C; inset, higher magnification). Tumor satellite
that was detected in the hemisphere contralateral to the main tumor
mass (D). Mouse nestin positive cells displayed various morphologies,
including rich arborizations (E) and spindle-shaped morphology (F).
Bars E, F 50 mm, A, B, C 100 mm, D 150 mm.
doi:10.1371/journal.pone.0035150.g002
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associated host cells after immunofluorescent double-labeling of
human and rat nestin in tissue from the biopsy xenograft model.
Along the invasive edge of the xenografts, we observed
interdigitation of elongated, bipolar rat nestin-positive cells and
tumor cells (Fig. 5A). Higher magnification revealed close physical
contact between the elongated, spindle-shaped cells of the host and
tumor cells with elongated morphology (Fig. 5B, C). We did not
observe a co-localization of these two markers in the same cell,
which would have indicated tumor-host cell fusion. However, we
cannot exclude the possibility that such fusion events occurred,
perhaps at very low frequency. Similar to the mouse xenograft
models, rat nestin was expressed in tumor vessels and in
glomeruloid microvascular proliferations in the biopsy xenografts
(Fig. 5D, E). In diffusely infiltrative xenograft tumors, host nestin-
stained cells were either elongated (invasive) cells with several
terminal and central processes (Fig. 5F) or spread-out cells that
resembled astrocytes (Fig. 5G).
Host nestin-positive cells comprise a significant portion
of the tumor mass
Quantification of the tumor areas in sections of U251 glioma
xenografts indicated that approximately 29% of the area
contained cells that stained positive for human nestin (Fig. 6A)
and 8% was positive for host mouse nestin (Fig. 6B), whereas 63%
was negative for both human and mouse nestin (Fig. 6D). The
areas that were devoid of human or mouse nestin-expressing cells,
likely contained other cell types of the tumor stroma or
extracellular matrix, which comprise a large portion of the tumor
bed in gliomas. Some of the areas lacking human and mouse
nestin expression included necrotic areas that were devoid of
DAPI-stained cell nuclei (Fig. 6C).
High cell proliferation is present within the tumor, at the
tumor edge, and in the SVZ ipsilateral to the tumor
We next used immunohistochemical double-labeling for mouse
or rat nestin and proliferating cell nuclear antigen (PCNA) or Ki-
67 to evaluate whether the infiltrative host cells were proliferating.
Such investigation could reveal information regarding whether
nestin-positive host cells proliferate at a distant site and then
migrate to the tumor or whether a few of such host cells first
migrate and then proliferate in the tumor context. In the mouse
model, cell proliferation was most pronounced at tumor edges and
focally around necrotic regions (Fig. 7A). At the tumor periphery,
the majority of proliferating cells were tumor cells, whereas the
brain parenchyma surrounding the tumor contained several host
(mouse) nestin-positive cells that expressed PCNA, suggesting that
these host cell were proliferating (Fig. 7B). The presence of a
glioma implant induced proliferation of host nestin-positive cells in
the ipsilateral, but not the contralateral SVZ (Fig. 7C). This may
suggest that glioma and/or the brain tissue surrounding the tumor
secrete soluble factors that may stimulate the proliferation of
nestin-positive host cells. Similarly, cell proliferation was observed
in the peritumor regions of biopsy xenografts in rats (Fig. 7D, E),
with the majority of proliferating cells being glioma cells. Higher
magnification revealed the presence of elongated bipolar cells that
expressed both rat nestin and the proliferation marker Ki-67
(Fig. 7F).
Some host nestin-positive cells display astrocyte
morphology
Because neural stem cells have been proposed to be a subset of
SVZ astrocytes, we labeled xenograft sections from tumors grown
in mouse and rat brain for rodent nestin and glial fibrillary acidic
Figure 3. Peritumor infiltration of rat nestin-positive cells in
human GBM biopsy xenografts. A low-generation xenograft lesion
exhibiting invasive migration of tumor cells in the corpus callosum to
the opposite hemisphere (A, arrows). Note also the infiltration of the
cortex and hippocampus by invasive tumor cells (dashed lines, outline
of cortical surface; dotted lines, outline of tumor border; blue, DAPI
nuclear stain). An angiogenic high-generation GBM implant with high
cell density and well-demarcated borders, dilated vessels and necrotic
areas (areas devoid of DAPI (blue)-stained cell nuclei) (B) (dashed lines,
outline of cortical surface; dotted lines, outline of tumor border; blue,
DAPI nuclear stain). Rat nestin positive cells (green) accumulate around
the human GBM xenograft border and infiltrate into the tumor (red,
human nestin immunoreactivity) (C). A halo of host nestin-positive cells
at the tumor border (D). Higher magnification of the xenograft lesion
showing infiltration of elongated host nestin-positive cells into the
tumor (E). tu tumor, bv blood vessel, HL, HR hippocampal formation left
and right sides, DF dorsal fornix. Bars E 200 mm, D 500 mm, C 1 mm, A,
B 2 mm.
doi:10.1371/journal.pone.0035150.g003
Figure 4. Expression of rat nestin in the host rat brain and
tumor microvessels. Rodent nestin-positive cells (brown) in the wall
of the third ventricle (arrowheads) (A). Weak, patchy expression of
nestin was observed in some normal cortical microvessels. Arrowheads
point to endothelial cells (B). Dilated tumor microvessel in a high-
generation xenograft showing strong, relatively uniform host nestin
expression (C). A tumor microvessel with normal, non-dilated morphol-
ogy showing similarly strong staining for host nestin (D). Bars 20 mm.
doi:10.1371/journal.pone.0035150.g004
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protein (GFAP), a marker for astrocytes. In the tumor border zone,
where mouse nestin-positive cells accumulated, elongated bipolar
cells expressed both nestin and GFAP. Mouse nestin-positive
blood vessels in the tumor were GFAP-negative (Fig. 8A, inset).
We then compared adjacent tissue sections from tumor-bearing
mouse brains stained for mouse nestin or GFAP. Large numbers of
nestin-positive host cells were found at the immediate tumor
border (Fig. 8C), whereas GFAP-positive host cells with typical
astrocytic morphology were distributed loosely in a halo more
distal to the zone containing mouse nestin-positive cells that
surrounded the D566 human glioma implants (Fig. 8B). Some
GFAP-positive cells were adjacent to and showed arbors
projecting onto blood vessels (Fig. 8B, inset). In the GBM biopsy
xenografts, similar peritumor accumulation of rat nestin positive
cells was seen, with significant numbers of cells expressing both rat
nestin and GFAP (Fig. 8D). In this case, both the xenograft as well
as host astrocytes were positive for GFAP. Double-stained cells in
the tumor periphery were often elongated with several terminal
processes (Fig. 8E); however, plump cells with astrocytic
morphology were also seen, possibly representing reactive
astrocytes (Fig. 8F, top). Rat nestin and GFAP double-positive
cells were more numerous in the tumor periphery, but were also
found in the tumor core (Fig. 8G).
Host nestin- and smooth muscle actin-positive cells: two
distinct cell populations that contribute to tumor
angiogenesis
Given our observation that host nestin-positive cells contributed
to the tumor neovasculature both in the mouse and in the rat
xenograft models, we attempted to evaluate their spatial location
in the vessels and mode of recruitment. Mouse nestin-positive cells
were incorporated into vessels both in the periphery and core of
U87 human glioma xenografts (Fig. 9A, B). Host cells with intense
mouse nestin staining were also recruited into the site of vessel
sprouting (Fig. 9C). Staining for smooth muscle actin (SMA),
which is a marker for blood vessel-associated pericytes, exhibited a
similar pattern as that for host nestin, highlighting microvessels in
the main tumor mass (Fig. 9D), as well as in the tumor invasive
edge (Fig. 9F). Mouse nestin also stained blood vessels in the
cerebellum of tumor-bearing mice (Fig. 9E), although no tumor
mass was apparent in the cerebellum. This may suggest that
glioma in the cerebral frontal lobe may exert ‘long-distance’
effects, which may lead to upregulation of nestin expression in the
cerebellar vasculature. SMA and nestin double-immunofluores-
cence labeling of U87 xenografts that were in the process of
vascularization revealed that SMA-positive cells and nestin-
positive cells were in close ‘pair-wise’ physical association with
Figure 5. Morphology of rat nestin-positive cells and structures
in invasive and angiogenic GBM biopsy xenografts. Elongated,
bipolar rat nestin-positive cells (green, arrowheads) accumulate at the
infiltrative edge of a biopsy xenograft (red) (A). Magnified view of cells
in the tumor invasive zone with infiltrative single glioma cells
[(arrowheads, rat nestin-positive cells (green); arrows, human nestin-
positive glioma cells (red)] (B, C). A rat nestin-positive host cell (green)
closely associated with an invasive human nestin-positive tumor cell
(red, arrow), with the two elongated cell bodies juxtaposed to each
other (arrowheads) (C). Rat nestin-positive vascular elements (green) in
a high-generation human GBM xenograft (red) that induces angiogen-
esis (D). Host nestin-positive glomerular microvascular proliferation
(green) typical of human GBM pathology recapitulated in the rat brain
(E). Elongated rat nestin-expressing cells with terminal processes and
star-shaped cells (green, arrowheads) in a GBM xenograft with locally
invasive growth (red) and induction of angiogenesis (arrow) (F). Cells
with astrocytic morphology stained for rat nestin (green, arrowheads) in
a low-generation highly infiltrative xenograft with low tumor cell
density (red) G). Bars B, C 10 mm, F 50 mm, A, D, E, G, H 100 mm.
doi:10.1371/journal.pone.0035150.g005
Figure 6. Quantification of areas with or without nestin
expression in U251 glioma implants. Representative images of
areas that contained cells expressing human nestin (red) (A) or host
mouse nestin (green) (B), or stained with DAPI (blue) (C). Area
measurements indicated that approximately 29% of the area contained
cells that expressed human nestin (red), 8% contained cells that
expressed mouse nestin (green), whereas 63% of the area was negative
(blue-grey) for both human and mouse nestin (D). Bars A, B, C 300 mm.
doi:10.1371/journal.pone.0035150.g006
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Figure 7. Cell proliferation at the tumor periphery in glioma xenografts. Confocal composite image of U251 human glioma xenografts in
mice (A, B, C), and biopsy GBM spheroid xenografts in rats (D, E, F). Low magnification image shows a halo of host nestin positive cells (green)
surrounding the tumor. Note the macroscopically demarcated border toward the brain tissue (A). Immunostaining of PCNA (red) at the tumor
periphery and peritumor region indicates active proliferation in these areas (arrows). Higher magnification from panel A reveals that the majority of
dividing cells are in the tumor, but some nestin-positive host cells in the peritumor brain tissue stain are also dividing (B). Extensive proliferation of
host nestin-positive cells in the mouse subventricular zone ipsilateral to the tumor (C). Photomicrographs taken at the tumor periphery (lower right
side of images, marked ‘tu’) and the surrounding brain tissue (upper left side of the images) reveal proliferating cells (Ki-67, green). Again, the majority
of proliferating cells are in the tumor, but proliferating cells are also in the adjacent brain (D, E). Magnified image from E showing double-labeled
dividing (Ki-67, green nuclei) rat nestin-positive cells (red cytoplasm) (F). Bars F 10 mm, D, E, B insert, C insert 50 mm, B, C 100 mm, A 1 mm.
doi:10.1371/journal.pone.0035150.g007
Figure 8. Localization of GFAP-expressing host cells and rodent nestin-positive cells in glioma xenografts. In mice, murine nestin-
expressing host cells (green) at the U251 tumor border and also infiltrating into the tumor (A). These cells did not stain for GFAP, and were shown to
be vascular elements. However, a few cells (yellow) expressed both mouse nestin and GFAP (A, inset, arrows). GFAP-expressing cells with
characteristic branched morphology (astrocytes) were more numerous in the host brain tissue further away from the tumor border (A, red, GFAP; B,
brown, GFAP). We also observed GFAP-positive cells with astrocyte morphology that extended astrocyte foot-like processes onto blood vessels in the
vicinity of D566 tumor implant (B inset). Mouse nestin (brown) was strongly expressed at the immediate tumor border (dotted line) (C). GBM biopsy
xenograft lesion showing a less demarcated front toward the brain tissue. Numerous double-immunostained cells were seen at the tumor border.
GFAP strongly stained host astrocytes as well as glioma cells (D, red, GFAP; green, rat nestin). GFAP and rat nestin co-stained some host cells that
showed diverse morphologies. Double-immunostained cells often had elongated cell bodies, with several terminal processes (E, F, red, GFAP; green,
rat nestin). An elongated GFAP and rat nestin positive cell within the tumor center, with branched terminal processes (G). U251 (A), D566 (B, C),
biopsy spheroid xenografts (D–G). tu tumor. Bars E, F 10 mm, G 15 mm, A insert 25 mm, B insert 75 mm, A, D 100 mm, B, C 500 mm.
doi:10.1371/journal.pone.0035150.g008
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each other; however, they comprised two distinct populations of
cells (Fig. 10A, B). Whereas SMA expression is expected to
indicate pericytes/mural cells, nestin expression is thought to
indicate endothelial progenitor cells. Both cell types were involved
in the onset of vascularization in U87 small satellites (Fig. 10C). In
addition, the leading edges of forming microvessels were capped
by ‘sleeves’ of smooth muscle actin-positive cells, suggesting a role
pericytes in the angiogenic process (Fig. 10D).
SDF-1 and its receptor CXCR4 are expressed in the tumor
and in the brain parenchyma surrounding the tumor
Because SDF-1 and its receptor CXCR4 are involved in glioma
invasion, we performed immunostaining for this ligand-receptor
pair. The invasive edge, as well as the tumor periphery, was
populated by SDF-1-expressing cells with elongated morphology
and several terminal processes, reminiscent of invasive neural
progenitors that were stained by host nestin (Fig. 11A, B). SDF-1
was also localized to peritumor blood vessels (Fig. 11B). Double-
staining for SDF-1 and CXCR4 confirmed their expression in an
increasing gradient toward the tumor periphery, as well as in a
decreasing gradient away from the tumor in the peritumor host
brain tissue (Fig. 11C, D). Both SDF-1 and CXCR4 were
expressed in the tumor core, with CXCR4 being primarily
localized around necrotic areas and more scattered elsewhere
(Fig. 11E, F).
Discussion
In this study we have evaluated the cellular host responses to
orthotopic xenografts of glioma cell lines and GBM biopsy
implants in rodent models. We observed that host stem/progenitor
cells identified by rodent nestin expression displayed tropism for
human glioma xenografts in both mice and rats, and that host cells
originated and migrated from the ipsilateral SVZ to xenografts.
We and others have previously reported specific tropism of
exogenous and endogenous NSPCs to glioma xenografts
[13,16,17]. During normal brain development, tissue regeneration
and learning in rodents, NSCs originate in the SVZ and follow the
rostral migratory stream to reach the olfactory bulb. This process
is tightly regulated, and the cells do not disperse into the brain but
rather follow a well-defined route [9]. In the pathological brain,
the migratory patterns of NSCs change, with fewer new cells found
in the olfactory bulbs and more cells found in the diseased cortex
and corpus callosum [29]. NSCs were recruited from the SVZ
ipsilateral to the tumor implant, while the contralateral NSC pools
did not appear to be affected. In GBM biopsy xenografts in rats,
the tumor border contained host nestin-positive cells with various
morphologies: some showed a bipolar morphology characteristic
of migrating cells with very thin elongated cell bodies, whereas
others had several processes and assumed a star-like appearance
characteristic of astrocytes. In low-generation invasive glioma
lesions, nestin-expressing single cells with astrocytic or bipolar
morphology were richly interwoven between infiltrating tumor
cells. Previous investigations have shown that nestin-positive
Figure 9. Participation of host nestin and smooth muscle actin-
expressing cells in tumor angiogenesis. Blood vessel lined with
mouse nestin-positive cells at the tumor periphery (A, arrows).
Widespread vascularization with mouse nestin-positive cells in the
tumor bed (B). Recruitment of mouse nestin-positive cells to a
sprouting blood vessel branch (C, arrow). Smooth muscle actin-positive
cells are also part of blood vessels in the brain tumor mass (D).
Sprouting of mouse nestin-positive small blood vessels in the
cerebellum of a glioma-bearing mouse (E, red dotted lines). Smooth
muscle actin-positive cells at the invasive tumor edge (F) (inset, mouse
nestin-positive blood vessel, blue, hematoxylin stain of cell nuclei).
D566 xenograft (A, C, E), U87 xenograft (B, D). Bars A, C, E 25 mm, F
100 mm, F insert 25 mm, B, D 500 mm, D insert 50 mm.
doi:10.1371/journal.pone.0035150.g009
Figure 10. Host mouse nestin and smooth muscle actin-
expressing cells are partners during glioma angiogenesis.
Close contact was observed between host nestin (green) and SMA
(red)-positive cells incorporated into blood vessels in a U87 xenograft
28 days post-implantation (A, higher power B; insets, nestin staining;
dotted circle, putative ‘peg-socket’ structure). Cell nuclei are stained
blue (DAPI). Onset of vascularization involving mouse nestin-(white
arrows) and SMA-positive cells (red arrows) surrounding a small tumor
satellite in A U87 xenograft 28 days post-implantation (C). Note the
localization of mouse nestin- and SMA-positive cells at the periphery of
this satellite, which descend in a pair-wise manner into the deeper parts
of larger satellites (A, B). High-magnification image of a branching
vessel in a D566 xenograft 10 days post-implantation showing SMA
immunostained cells at the luminal lining and nestin expression at the
sprouting front (D). U87 xenograft (A, B, C), D566 xenograft (D). Bars D
insert 20 mm, B and B insert 25 mm, A and A insert 50 mm.
doi:10.1371/journal.pone.0035150.g010
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neural precursor cells accumulate at the site of mechanical brain
injury, and by day 14 post-surgery, these cells display the branched
morphology of reactive astrocytes [17]. On the other hand, NSCs
around tumors displayed a bipolar morphology and persisted for
at least 30 days, although in lower numbers, around the lesions. In
comparison, our high generation biopsy spheroid-derived lesions
grew in an obstructive way, creating a mass effect similar to the
growth pattern of the glioma cell lines transplanted by Glass et al.
(2005). Similarly, we generally observed a bipolar morphology in
the nestin-positive host population of these lesions. In contrast, in
low-generation xenografts, the tumor cells seamlessly infiltrated
the brain, and we generally observed nestin-positive cells with an
astrocytic morphology, comparable to what was seen at the site of
mechanical injury (Glass et al., 2005). Possibly, in low-generation
biopsy xenografts, after repair/regeneration of the injection site,
the dispersed single glioma cells failed to stimulate further influx of
neural progenitors from the SVZ. The previously recruited
progenitors may have differentiated and displayed morphology
similar to mature astrocytes.
The high (fifth) generation glioma implants were double-stained
for GFAP and rat-specific nestin to evaluate the glial nature of the
infiltrating host cells. GFAP stained both mature astrocytes and
glioma cells. At the tumor border, the vast majority of nestin-
positive cell bodies also expressed GFAP. These cells had the
elongated cell bodies of invasive bipolar cells, although some also
had several end-processes, resembling astrocytes. The bipolar cells
may have been incoming neural progenitors, whereas those with
branched morphology may have been reactive astrocytes. In the
tumor, cells with elongated morphology, as well as cells with
astrocytic morphology stained positively for both rat nestin and
GFAP.
In both mice and rats, a host nestin-positive cell population
(endothelial progenitors) contributes to human xenograft growth
by assembling into the glioma microvasculature. In contrast, non-
pathological brain microvessels showed little or no nestin
expression. This confirms xenograft data from other tumor types,
where nestin positive cells in tumor vessels have been identified as
endotheliocytes [30]. In the high (fifth) generation GBM spheroid
xenografts, we observed glomerulus-like microvascular prolifera-
tions, which stained intensely for host (rat) nestin. Such
glomerulus-like vessels are a hallmark of GBM pathology [31],
and likely represent non-functional vessels that might be
responsible for generating the hypoxic environment in gliomas
[32]. It is important to note that vascular endothelial growth factor
(VEGF), when processed by matrix metalloprotesases (MMPs),
causes generation of dilated, glomerulus-like vessels in tumors,
whereas in the absence of MMPs more vascular sprouting is
observed, which resembles the normal blood vasculature [33].
Because glioma pathology, invasion and angiogenesis are closely
tied to the activity of various MMPs [34], and based on our
current data, it is likely that recruitment of rat nestin-positive host
cells by glioma reflects the intricate processes of glioma biology,
including tumor hypoxia and angiogenesis.
In the mouse xenografts, staining for both host nestin and SMA
showed similar staining pattern, illuminating the vascular network
in the tumor bed. These two markers did not co-localize, but were
expressed by two distinct, closely associated cell populations that
together generated tumor microvessels. Based on their elongated
Figure 11. Expression pattern of SDF-1 and CXCR4 in glioma xenografts. SDF-1 (brown, A and B; red, C and E) is expressed at the tumor
edge (A, B, C) and in the tumor center (E). SDF-1 staining was present in the peritumor blood vessels, where some of the signal appeared to be
associated with the luminal surface of such blood vessels, indicating the presence of ‘SDF-1 trap’ in these vessels (B). SDF-1 expression (red) also
appeared to extend beyond the tumor edge (C), where reactive astrocytes are known to express high levels of SDF-1. CXCR4 (blue) showed high
expression at the tumor edge and in the tumor center (D, F). D566 xenograft (A, B), U251 xenograft (C–F). Dotted lines in C, D indicate tumor edge.
Bars A, B 100 mm, C–F 200 mm.
doi:10.1371/journal.pone.0035150.g011
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morphology, luminal localization and relative abundance, host
nestin-expressing cells are suggested to be endothelial cells or
endothelial progenitors [19]. Indeed, the endothelial cell marker
CD31 has been found co-expressed with nestin in the tumor
vasculature of orthotopic xenografts of the pancreas in the nestin-
GFP mice [30]. On the other hand, SMA is a marker of smooth
muscle cells and mature pericytes, which may be derived from
hematopoietic stem cells or bone marrow-derived pericyte
progenitor cells that are recruited to the brain during glioma
angiogenesis, suggesting a ‘long-distance’ effect in recruitment of
cells that contribute to tumor angiogenesis [35,36,37,38].
Furthermore, direct contacts between endothelial cells and smooth
muscle cells have been described as ‘peg-socket’ contacts, where
the basement membrane is absent. We detected structures
resembling such contacts between SMA-positive cells and mouse
nestin-positive cells (Fig. 10B). These cell-to-cell communication
points have been described to contain tight, gap, and adherence
junctions [39]. The contact between endothelial cells and pericytes
leads to activation of latent TGF-b, which promotes pericyte
differentiation via the ALK5 Smad2/3 signaling pathway [39].
Endothelial cells line the inside of blood vessels, whereas pericytes
line the outside surface and interact with the basement membrane
that surrounds the blood vessels [40]. In an analysis of the spatial
localization of endothelial cells (CD31+) and pericytes (SMA+)
during angiogenesis in spontaneous tumors of the pancreatic islet
as well as in transplanted mammary and lung carcinomas,
Morikawa et al found that, similar to our data, there was SMA-
positive pericytic coverage or ‘sleeves’ at the leading edges of
vascular sprouts [41]. In their study, pericytes in capillary
microvessels formed by angiogenesis uniformly expressed SMA,
in contrast to corresponding normal tissue, in which only arterioles
and venules had SMA-positive adventitial cells. Our data show
that in the brain, tumor capillaries were richly populated by SMA-
positive accessory (pericytic/mural) cells, whereas the normal
brain vasculature did not express SMA. In a recent study of 40
GBM patients Sica et al reported on the presence of nestin-
positive, SMA-positive and CD105-positive cell populations
associated with microvasculature in the peritumor area [42]. High
microvascular density in the peritumor area correlated with a
shorter survival time of the GBM patients, which suggests that the
cell populations attracted by glioma may have an influence on the
clinical progression of the disease.
The SDF-1/CXCR4 signaling axis has been shown to be a
major player in the dissemination and metastasis of tumor cells,
e.g., in breast cancer metastasis to the bone marrow [43], VEGF-
induced neovascularization and retention of myeloid cells in
normal and cancerous tissues [44], recruitment of vascular
progenitors to glioma [38], and glioma invasion and growth
[45,46]. This chemokine/receptor system may be also involved in
the homing of bone marrow-derived hematopoietic cells or neural
stem or progenitor cells to tumors [47,48]. In GBM, the expression
levels of both SDF-1 and its receptor correlate positively with
tumor grade, with CXCR4 being mainly localized to tumor
endothelial cells, which likely use the SDF-1/CXCR4 axis to
migrate during angiogenesis [49]. Exogenous NSCs that target
human glioma xenografts in mouse brain localize to the tumor
(including the hypoxic regions) and tumor edge, which displayed
high levels of SDF-1 expression [50]. In normal brain, the
expression pattern of SDF-1 and CXCR4 has been shown to
coincide with that of NPCs, with virtually all nestin-positive cells in
the SVZ also expressing CXCR4 [51]. Functional studies have
confirmed the role of the SDF-1/CXCR4 system in NPC
migration after neurological damage. For example, in cerebral
stroke, the migration of NSCs to the injury site was attenuated by
adding anti-SDF-1 blocking antibodies [52]. SDF-1 also promotes
adult NPC proliferation as well as migration [53,54,55], and the
SDF-1/CXCR4 signaling axis is involved in trafficking of normal
stem cells as well as in metastasis of cancer cells [56]. We found
that the location (peritumor halo, scattered single infiltrating cells
in the tumor, and expression in tumor-associated blood vessels)
and morphology (elongated single cells, cells with astrocytic
morphology and small vessels) of SDF-1-expressing cells were
identical to those of mouse nestin-expressing cells. This suggests
that NPCs may express SDF-1, possibly indicating an autocrine
stimulatory loop, or ‘trapping’ of SDF-1 by the recruited
progenitors and vascular structures that arise from these cells.
In vivo migration of NSPCs is induced by vascular endothelial
and astrocytic expression of SDF-1 [57]. Similarly, we observed
SDF-1 expression in cells with astrocytic as well as endothelial
morphology (Fig. 11), in addition to invasive cells that resembled
infiltrating NPCs. CXCR4 expression localized to the same areas
as that of SDF-1, but seemed to be less abundant both at the
tumor-bordering brain and the tumor core. The exception was
stronger expression of CXCR4 around necrotic foci as compared
to SDF-1. Necrotic foci and the pseudopalisading regions are
hypoxic and are the main sites of HIF-1a and VEGF expression in
glioblastoma [58,59], which may result in high expression of
CXCR4. Indeed, over-expression of CXCR4 has been shown to
be mediated by HIF-1 and VEGF [60], which is the main
hypoxia-induced angiogenic pathway present in both vascularized
cell line-based xenografts and in the high-generation lesions in the
biopsy xenograft model [24].
Finally, the nestin-positive host cells recruited by gliomas may
have effects other than those discussed above. For example, glioma
cells generate considerable amounts of glutamate, which can lead
to excitotoxity of neurons in the brain parenchyma surrounding
the glioma mass, thus promoting the invasive migration and
growth of glioma [61]. The presence of nestin-positive stem or
progenitor cells in and around glioma may have protective effects
against glutamate cytotoxicity. On the other hand, gliomas may
co-opt some of the physiological properties of neural and
mesenchymal stem cells for their advantage. Because neural and
mesenchymal stem cells can release large amounts of TGF-b, a
cytokine with immosuppressive potential, the anti-glioma immune
response may be attenuated, resulting in tumor ‘escape’ from
normal immunological surveillance [62,63]. It should be noted
that glioma cells may communicate with host cells in even more
intricate ways; for instance, cell-cell fusion or horizontal gene
transfer may result in exchange of genetic material between glioma
and host cells [64,65]. Furthermore, microvesicles (exosomes) that
contain mRNA, microRNA and angiogenic proteins have been
shown to be released by glioma cells, which can be taken up by
normal host cells, such as brain microvascular endothelial cells
[66]. A more recent and striking finding has been that
glioblastoma stem-like cells can give rise to tumor endothelium
[67,68]. These data, together with our findings presented here,
underscore the complex nature of malignant gliomas. Indeed, in
addition to the cell types described in our study, the repertoire of
cells attracted by or interacting with glioma is extremely diverse
and includes neurons, oligodendrocytes, astocytes, microglia, cells
of the immune system (B lymphocytes, various populations of T
lymphocytes, macrophages), mast cells, and numerous others
[69,70,71]. These cell types contribute to the microenvironment in
which the tumor cells can proliferate, invade and destroy the
normal brain parenchyma. However, some of these tumor-
targeting host cells may serve also a protective function of the
host by inhibiting tumor growth and invasion. It is hoped that
further elucidation of the tumor and host interactions may aid the
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development of novel treatments for glioma, one of the most
dreaded brain cancers.
Materials and Methods
Ethics statement
All patients gave a written informed consent for tumor biopsy
collection and signed a declaration permitting the use of their biopsy
specimens in scientific research. The study was approved by the
Norwegian Regional Research Ethics Committee (http://
helseforskning.etikkom.no/ikbViewer/page/komiteerogmoter/vest/
medlemmer?p_dim=34986&lan=2&_ikbLanguageCode=n&region=
10796). All protocols for the experiments involving rats, the
handling of the animals and the surgical procedures were done in
accordance with the Norwegian Animal Act and the local Ethics
Committee approved the protocol. Mice were housed in a
vivarium accredited by the American Association for Accredita-
tion of Laboratory Animal Care. All protocols for mouse
experiments were approved by the City of Hope Institutional
Animal Care and Use Committee.
Intracerebral implantation of glioma cell lines
The U251 and U87 human glioma cell lines were purchased
from ATCC, the D566 cell line was a gift from Dr. Darell Bigner
(Duke University, Durham, NC). Orthotopic tumor xenografts
were generated by implanting these human glioma cell lines into
the brains of 8-week-old female athymic nude/nude mice (Charles
River). Animals were anesthetized (132 mg/kg ketamine and
8.8 mg/kg xylazine) and received stereotactically guided injections
of 1226105 tumor cells in sterile PBS (2 mL) through a 30-gauge
Hamilton syringe over 3–5 min into the right forebrain (2 mm
lateral, 0.5 mm anterior to bregma, tracked from a depth of
2.5 mm to 2.25 mm to 2.0 mm; 0.667 mL of cell suspension was
injected at each depth) [13,72]. The needle was retracted over 2–
4 min, the burr hole occluded with bone-wax, Betadine applied to
the surgical area, and the skin closed with skin glue or sutures.
Analgesic (Buprenorphine, 0.05 mg/kg) was administered intra-
peritoneally relieve post-operative pain. When mice appeared to
be in discomfort or distress, as judged by independent animal care
personnel with no knowledge of the protocol design, animals were
euthanized.
Intracerebral implantation of glioblastoma biopsy
spheroids
Human GBM biopsy spheroids were prepared and maintained
as described previously [26]. Briefly, patient biopsies obtained at
surgery were transported to the tissue culture laboratory on ice.
Thereafter, the tissue was minced in a laminar flow hood under
sterile conditions using crossed scalpel blades. Tissue pieces (,0.5–
1 mm3) were incubated (37uC, 5% CO2) in flasks with agar
overlay in Dulbecco’s Modified Eagle’s Medium supplemented
with 10% fetal calf serum, 2 mM L-glutamine and non-essential
amino acids. Tumors from nude rat brains were harvested and
prepared similarly and were then implanted intracranially into
another group of nude rats in order to grow the ‘higher
generation’ tumors. Spheroids formed after a few days to one
week in culture. Spheroid implantation into nude rats was
performed as previously described [73]. Briefly, a burr hole was
drilled 1 mm posterior to the bregma and 3 mm to the right of the
midline suture, and 15 spheroids (diameter 400–600 mm) were
injected into the corpus callosum region (at 2.5 mm depth) using a
Hamilton type 7125 syringe (Hamilton, Bonaduz, Switzerland)
before the wound was closed and the animals returned to their
cages. The experimental protocol was approved by the Norwegian
Animal Research Authority.
Tissue processing
At varying time points after tumor cell implantation (U251, 76
days; U87, 28 days, D566, 10 days), mice were perfused
intracardially with 4% paraformaldehyde (PFA) in PBS. The
brains were harvested and post-fixed (4% PFA, 48 h, 4uC). For
frozen sections, post-fixed brains were incubated (48 h, 4uC) in
30% (w/v) sucrose in PBS, embedded in optimal cutting
temperature (OCT) compound and cryosectioned (10 mm thick-
ness). Sections were thaw-mounted onto glass slides, air-dried and
stored (220uC) until further processing. For paraffin-embedded
sections, post-fixed brains (without incubation in sucrose) were
embedded in paraffin and sectioned (5 mm thick), and sections
were mounted on glass slides and stored (room temperature) until
further processing. Nude rats were intracardially perfused with
sterile saline and the brains frozen in isopentane chilled by dry ice.
Cryosections (10 mm) were mounted on glass slides and stored
(280uC) until further processing.
Immunohistochemistry
Immunohistochemical staining (IHC) of cryosectioned or
paraffin-embedded tissues was carried out as described previously
[74]. Frozen sections were rehydrated in PBS, endogenous
peroxidase activity was blocked (0.3% hydrogen peroxide in
methanol, 20 min at room temperature) (for fluorescent IHC, no
peroxidase blocking was performed), sections were blocked for
non-specific antibody binding (blocking solution: 5% BSA, 3%
normal serum from species in which secondary antibody was
made, 0.1% Triton X-100 in PBS, 1 h at room temperature; or
5% BSA in PBS, 20 min). Sections were incubated (4uC,
overnight) with primary antibodies in blocking solution, followed
by several washes in PBS and reaction with biotinylated secondary
antibodies (for some experiments, fluorophore-conjugated second-
ary antibodies were used). Immunostaining was visualized by
chromogenic reaction (peroxidase/DAB) using the Vectastain
Elite ABC kit (Vector Labs) or by reaction with fluorescently-
labeled avidin.
Paraffin-embedded sections were deparaffinized, followed by
antigen retrieval (10 mM citric acid, pH 6.0, and heating in
microwave oven [265 min] or steam cooker, for all primary
antibodies, except for SDF-1 and smooth muscle actin for which
1 mM EDTA, pH, 8.0, and heat treatment was used). Sections
were then processed for peroxidase/DAB or fluorescent IHC. For
fluorescent double-labeling IHC, primary antibodies generated in
different species were used. For fluorescent double-labeling with
primary antibodies from the same species, we used a modified
IHC method using an avidin-biotin blocking kit and blocking with
non-biotinylated secondary antibodies. Primary antibodies were
omitted, and secondary antibodies were included during staining
of tissue sections that served as negative controls.
Primary antibodies used were: CXCR4 (rabbit polyclonal,
5 mg/mL final concentration, Abcam, ab2074), GFAP (rabbit
polyclonal, 75 mg/mL, Sigma, G9269; chicken polyclonal, 1:1000
dilution, Chemicon, AB5541), human nestin (rabbit polyclonal,
1:200, Chemicon, AB5922; mouse monoclonal, 5-10 mg/mL,
Chemicon, MAB5326), Ki-67 (rabbit polyclonal, 1:200, Chemi-
con, AB9260; rat monoclonal, 73 mg/mL Dako, M7249), mouse/
rat nestin (mouse monoclonal, 5–10 mg/mL, Chemicon,
MAB353), PCNA (mouse monoclonal, 10 mg/mL, Chemicon,
MAB424), SDF-1 (mouse monoclonal, 5 mg/mL, R&D Systems,
MAB350), smooth muscle actin (mouse monoclonal, 0.7 mg/mL,
Dako, M0851).
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Secondary antibodies used were: anti-mouse IgG (biotinylated,
2 mg/mL, Vector Labs, BA-2001), goat-anti-mouse IgG1 (FITC-
conjugated, 5 mg/mL, Southern Biotech, 1070-02), anti-mouse
IgG (non-biotinylated, 5 mg/mL, Vector Labs, AI-2001), anti-
rabbit IgG (biotinylated, 2 mg/mL, Vector Labs, BA-1000), goat-
anti-rabbit IgG (Texas Red conjugated, 5 mg/mL, Southern
Biotech, 4010-07) anti-rat IgG (biotinylated, 2 mg/mL, Vector-
Labs, BA-4001), goat-anti chicken biotinylated (7.5 mg/mL,
Vector Labs, BA-9010).
Chromophores and other reagents used for immunohistochem-
istry: Avidin-AMCA (1 mg/mL, Vector Labs, A-2008), ExtrA-
vidin-Cy3 (1:200, Sigma, E4142), Avidin-FITC (1 mg/mL, Vector
Labs, A-2011), Avidin-Texas Red (1 mg/mL, Vector Labs, A-
2016), Avidin-biotin blocking kit (Vector Labs, SP-2001), bovine
serum albumin (Sigma, A7906), citric acid (Sigma, C8532),
Cytoseal 60 (VWR, 48212-187), DAB (3,39-diaminobenzidine)
substrate kit (Vector Labs, SK-4100), fluorescent mounting
medium (Dako, S3023), DAPI (1 mg/mL, Sigma, D-9542),
Hematoxylin (Sigma, HHS32), normal horse serum (Vector Labs,
S-2000), normal rabbit serum (Vector Labs, S-5000), PBS
(phosphate buffered saline, pH 7.4), Triton X-100 (Sigma,
T9284), Vectastain Elite ABC kit (Vector Labs, PK-6100).
Image processing
Low- and high-magnification images were obtained using a
Nikon Eclipse TE2000-U microscope (Nikon Instruments)
equipped with brightfield and fluorescence illumination. Images
were recorded and stored using SPOT Advanced and Adobe
Photoshop software. Some images were obtained by confocal
microscopy using a Zeiss LSM 510 confocal microscope (Carl
Zeiss Microimaging Inc.), and multi-panel composite images were
constructed using the MetaMorph software. NIH Image J software
was used for area measurements of tissues stained for human
nestin and mouse nestin.
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